BeiGene, Ltd. — Q1 2024 Form 10-Q Summary
Reporting period: Three months ended March 31, 2024; interim financial statements are unaudited and prepared under U.S. GAAP. The filing identifies the registrant as BeiGene, Ltd. (not “Beone Medicines Ltd.”). Amounts below are U.S. dollars.
Business context and financial performance
BeiGene is a global oncology company with commercial products including BRUKINSA (zanubrutinib), tislelizumab and licensed medicines. It operates in one pharmaceutical-products segment.
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total revenue | $751.7 million | $447.8 million | +67.9% |
| Net product revenue | $746.9 million | $410.3 million | +82.0% |
| Gross profit | $626.7 million | $366.0 million | +71.2% |
| Operating expenses | $888.1 million | $737.3 million | +20.5% |
| Operating loss | $(261.3) million | $(371.3) million | Loss narrowed |
| Net loss | $(251.2) million | $(348.4) million | Loss narrowed |
| Basic and diluted loss per share | $(0.19) | $(0.26) | |
| Operating cash flow | $(308.6) million | $(563.8) million | Cash use decreased |
Product gross margin was 83.3%, up from 80.1%, mainly reflecting a higher proportion of BRUKINSA sales. Interest income, net, was $16.2 million; income tax expense was $7.7 million. The company reported $88.7 million of share-based compensation expense. Adjusted operating loss, a non-GAAP measure, was $147.3 million versus $275.9 million; the company excludes items including share-based compensation, depreciation and amortization in this measure.
Revenue mix and material period changes
- BRUKINSA revenue was $488.5 million, up 131.1% year over year. Management attributed growth to U.S. and European expansion; U.S. sales were $351.5 million and Europe sales $66.8 million.
- Tislelizumab revenue was $145.3 million, up 26.5%. China sales growth was attributed to broader reimbursement, hospital listings and market penetration.
- Licensed products also contributed: XGEVA revenue was $43.4 million, BLINCYTO $14.4 million and KYPROLIS $14.1 million. REVLIMID revenue declined 47.2% to $12.2 million.
- Collaboration revenue fell 87.4% to $4.7 million, primarily because prior-year revenue included deferred amounts from Novartis collaborations that were terminated in 2023. Q1 2024 collaboration revenue was mainly under the Novartis China broad-markets agreement.
- R&D expense rose 12.7% to $460.6 million, including $35.0 million in upfront and development milestone fees. SG&A rose 30.1% to $427.4 million as the company expanded commercial activities, particularly for BRUKINSA in the U.S. and Europe.
Cash, debt and liquidity
- Cash, cash equivalents and restricted cash were $2.807 billion at March 31, 2024, down from $3.186 billion at year-end 2023. The balance sheet reported cash and cash equivalents of $2.793 billion; restricted cash was $14.1 million. Short-term investments were nil.
- Total debt was approximately $1.026 billion, including $827.0 million of short-term debt and $199.0 million of long-term bank loans. Approximately $827.0 million is due within 12 months. The company said it expects to repay and/or refinance these borrowings and was in compliance with material debt covenants.
- Cash used in investing activities was $209.8 million, including $156.6 million of property and equipment purchases and $31.8 million for in-process R&D. Financing activities provided $162.3 million, chiefly from short-term loans.
- Management expects existing cash and cash equivalents to fund operating expenses and capital expenditure requirements for at least 12 months after issuance of the statements. It also noted that most STAR Offering proceeds are restricted to specified uses; $961.0 million remained at quarter-end.
- Material commitments included $457.0 million remaining for Amgen pipeline co-development, $93.5 million of purchase commitments, $61.6 million of capital commitments and $8.9 million of investment funding commitments.
Outlook, developments and risks
- Management said it expects losses to decrease in the near term as product sales growth exceeds expense growth, while also expecting continued losses and increased investment in R&D, manufacturing and commercialization. The filing says selling and marketing expenses are expected to increase in 2024, with SG&A as a percentage of revenue expected to improve gradually. No specific revenue or earnings guidance was provided.
- On March 7, 2024, the FDA granted accelerated approval for BRUKINSA with obinutuzumab for certain adults with relapsed or refractory follicular lymphoma, its fifth U.S. B-cell malignancy indication. On March 14, the FDA approved TEVIMBRA for certain patients with esophageal squamous cell carcinoma; U.S. availability was expected in the second half of 2024. The FDA accepted a TEVIMBRA gastric/GEJ cancer application, with an action date expected in December 2024. After quarter-end, the European Commission approved tislelizumab for three NSCLC indications.
- Unusual item: the first-quarter divestiture of substantially all Pi Health business assets generated a $3.7 million pretax gain and a $40.8 million preferred-stock investment. The divestiture was not treated as a discontinued operation.
- BRUKINSA faces patent litigation brought by Pharmacyclics; the case was stayed pending a USPTO review. The USPTO granted BeiGene’s review petition on May 1, 2024, with a final decision expected within 12 months. BeiGene also filed patent suits against Sandoz and MSN over their generic applications; the company said the composition-of-matter patent remains in force until 2034.
- Key risks highlighted include continued net losses and cash burn, refinancing short-term debt, clinical and regulatory uncertainty, competition and reimbursement/pricing pressure, manufacturing and supply dependence, intellectual-property disputes, foreign-exchange exposure and evolving PRC data, regulatory and cross-border capital rules. A 100-basis-point increase in rates on floating-rate debt would raise annual pretax interest expense by about $6.7 million. RMB depreciation reduced Q1 cash by $22.4 million.
Important facts for investors to verify
- Whether BRUKINSA revenue growth and its contribution to product gross margin are sustained across markets.
- The timing and outcome of TEVIMBRA regulatory decisions and the commercial uptake of new indications.
- Ability to refinance or repay the $827.0 million of debt due within 12 months, and compliance with debt covenants.
- Cash burn, capital spending and commitments—including Amgen co-development funding—and progress toward management’s stated path to sustainable profitability.
- Developments in the Pharmacyclics and generic-entry patent proceedings, and any effects on BRUKINSA’s commercial protection.